Edwards Lifesciences Corporation $EW Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. sold 69,029 shares of Edwards Lifesciences Corporation, reducing its holdings by 54.9% during the first quarter, leaving it with 56,647 shares valued at approximately $4.1 million.
• Wall Street analysts have a positive outlook for Edwards Lifesciences, with target prices raised by several firms; the average rating is "Moderate Buy" with an average price target of $85.90.
• The company reported earnings of $0.67 per share for the last quarter, surpassing estimates and showing an 11.9% year-over-year revenue increase of $1.53 billion.

Candriam S.C.A. cut its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 54.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 56,647 shares of the medical research company's stock after selling 69,029 shares during the period. Candriam S.C.A.'s holdings in Edwards Lifesciences were worth $4,106,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the fourth quarter worth about $27,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $29,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $29,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the sale, the vice president owned 50,356 shares of the company's stock, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock valued at $1,897,762 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on EW shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Citigroup restated a "buy" rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Stock Down 1.1%

Shares of EW stock traded down $0.9090 during mid-day trading on Monday, hitting $80.9210. 4,393,047 shares of the stock traded hands, compared to its average volume of 4,195,043. The stock has a market cap of $47.51 billion, a P/E ratio of 11.64, a P/E/G ratio of 3.95 and a beta of 1.08. The stock's fifty day moving average is $77.71 and its two-hundred day moving average is $74.79. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences's revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.